Skip to Content

Company Profile

Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. We focus on addressing what we believe are the primary barriers that limit consistent, reliable, and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. We apply our proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.

Stock Chart

Data Provided by Refinitiv. Minimum 15 minutes delayed.